Hsp90抑制剂NVP-AUY922单药及联合用药在肿瘤治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2015.03.021

摘要/Abstract

摘要：

热休克蛋白(Hsp90)是一类高度保守的蛋白质。近年的研究表明,Hsp90与肿瘤的发生及转移有高度的相关性,因此一些小分子Hsp90抑制剂被发现具有广泛的抗肿瘤增殖及转移的作用。NVP-AUY922是其中一种具有吡咯骨架的人工合成制剂,由于它具有毒副作用小和结构稳定等优点,被人们广泛考虑作为新一类的抗肿瘤药物使用。本篇综述主要就AUY922单药及与其他药物联合使用治疗肿瘤的研究进展做一综述。

关键词: Hsp90抑制剂, 肿瘤, 靶向治疗, NVP-AUY922

Abstract:

Heat shock protein 90(Hsp90)is a highly conserved protein which have been proved to play an important role in the development and progression of malignant transformation.As one of small molecule inhibitors that has been detected to have potent antitumor activity in a wide range of malignancies,NVP-AUY922 is a pyrazole scaffold drug with many advantages such as low toxicity and stable structure.As a result of this,NVP-AUY922 is extensively considered as a new promising kind of anti-tumor drug.This review intends to update the reader on advances made over the past four years in the clinical development of NVP-AUY922 in advanced cancers.

Key words: Hsp90 inhibitor, Tumor, TKI, NVP-AUY922

中图分类号:

R730.53

张佳文, 曹京燕, 金时综述, 于雁审校. Hsp90抑制剂NVP-AUY922单药及联合用药在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(3): 284-288.

ZHANG Jiawen,CAO Jingyan,JIN Shi,YU Yan. The advances of the HSP90 inhibitor NVP-AUY922:applied alone or in combination with anti-tumor treatment[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 284-288.

参考文献

1 肖砾,陶茂萱.健康素养研究进展与展望[J].中国健康教育,2008,24(5):361-364.
2 王绯,杨永平.Hsp90抑制剂靶向治疗癌症研究进展[J].解放军医学杂志,2006,31(3):274-275.
3 Whitesell L,Lindquist SL.Hsp90 and the chaperoning of cancer [J].Nature Reviews Cancer,2005,5(10):761-772.
4 Chen MH,Chiang KC,Cheng CT,et al.Antitumor activity of the combination of an Hsp90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma [J].Oncotarget,2014,5(9):2372-2389
5 Trepel J,Mollapour M,Giaccone G,et al.Targeting the dynamic Hsp90 complex in cancer[J].Nature Reviews Cancer,2010,10(8):537-549.
6 Camidge DR,Doebele RC.Treating ALK-positive lung cancer-early successes and future challenges [J].Nat Rev Clin Oncol,2012,9(5):268-277.
7 Smith CC,Wang Q,Chin CS.Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia [J].Nature,2012,485(7397):260-263.
8 Taipale M,Jarosz DF,Lindquist S.Hsp90 at the hub of protein homeostasis:emerging mechanistic insights[J].Nat Rev Mol Cell Biol,2010,11(7):515-528.
9 Solit DB,Chiosis G.Development and application of Hsp90 inhibitors [J].Drug Discovery Today,2008,13(1):38-43.
10 Cowen LE,Singh SD,Khler JR,et al.Harnessing Hsp90 function as a powerful,broadly effective therapeutic strategy for fungal infectious disease[J].Proc Natl Acad Sci USA,2009,106(8):2818-2823.
11 Lee KH,Lee JH,Han SW,et al.Antitumor activity of NVP-AUY922,a novel heat shock protein 90 inhibitor,in human gastric cancer cells is mediated through proteasomal degradation of client proteins[J].Cancer Science,2011,102(7):1388-1395.
12 Lang SA,Klein D,Moser C,et al.Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo[J].Molecular Cancer Therapeutics,2007,6(3):1123-1132.
13 Moser C,Lang SA.Targeting Hsp90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer[J].Anticancer Research,2012,32(7):2551-2561.
14 张玮芳,彭大为.进展期胃癌分子靶向治疗的研究进展[J].海南医学,2014,(9):1321-1323.
15 Sessa C,Shapiro GI,Bhalla KN,et al.First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors [J].Clinical Cancer Research,2013,19(13):3671-3680.
16 Jensen MR,Schoepfer J,Radimerski T,et al.NVP-AUY922:a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models [J].Breast Cancer Res,2008,10(2):R33.
17 Caldas-Lopes E,Cerchietti L,Ahn JH,et al.Hsp90 inhibitor PU-H71,a multimodal inhibitor of malignancy,induces complete responses in triple-negative breast cancer models [J].Proc Natl Acad Sci USA,2009,106(20):8368-8373.
18 Varticovski L.A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas[J].Nature Medicine,2009,15(12):1369-1376.
19 Garon EB,Finn RS,Hamidi H,et al.The Hsp90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth [J].Molecular Cancer Therapeutics,2013,12(6):890-900.
20 Ueno T,Tsukuda K,Toyooka S,et al.Strong anti-tumor effect of NVP-AUY922,a novel Hsp90 inhibitor,on non-small cell lung cancer[J].Lung Cancer,2012,76(1):26-31.
21 Garon EB,Moran T,Barlesi F,et al.Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated,advanced non-small cell lung cancer(NSCLC)[C].J Clin Oncol(Meeting Abstracts),2012,30(5):7543-7544.
22 Zhou Q,Zhang XC,Peng B,et al.A phase II cluster study of single agent AUY922,BYL719,INC 280,LDK378 and MEK162 in Chinese patients with advanced non-small cell lung cancer(NSCLC)[C].J Clin Oncol(Meeting Abstracts),2014,32(5):8122-8125.
23 Samuel TA,Sessa C,Britten C,et al.AUY922,a novel Hsp90 inhibitor:final results of a first-in-human study in patients with advanced solid malignancies [J].J Clin Oncol,2010,28(5):2528-2529.
24 Ku SY,Lasorsa E,Adelaiye R,et al.Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate Cancer [J].PLoS One,2014,9(7):e103680.
25 Doi T,Onozawa Y,Fuse N,et al.Phase I dose-escalation study of the Hsp90 inhibitor AUY922 in Japanese patients with advanced solid tumors[J].Cancer Chemotherapy and Pharmacology,2014,74(3):629-636.
26 Chen SM,Guo CL,Shi JJ,et al.Hsp90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer[J].International Journal of Cancer,2014,135(10):2462-2474.
27 Best OG,Mulligan SP.Heat shock protein-90 inhibitor,NVP-AUY922,is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype [J].Leukemia & Lymphoma,2012,53(11):2314-2320.
28 Chen MH,Lin KJ,Yang WLR,et al.Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma[J].Cancer,2013,119(2):293-303.
29 Perez CA,Velez M,Raez LE,et al.Overcoming the resistance to Crizotinib in patients with non-Small cell lung cancer harboring EML4/ALK translocation[J].Lung Cancer,2014,84(2):110-115.
30 万静华,傅振坤.抑制性协同刺激分子B7-H4在女性常见恶性肿瘤中的研究进展[J].实用肿瘤学杂志,2015,29(1):53-56.
31 Hashida S,Yamamoto H,Shien K,et al.Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors[J].Oncology Reports,2015,33(3):1499-1504.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[4]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[5]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[6]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[7]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[8]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[9]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[10]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	阚钧, 周岱翰综述, 张恩欣审校. 肿瘤合并心血管疾病的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 558-561.
[14]	顾琦晟综述, 李继坤审校. 锰超氧化物歧化酶在肿瘤发生发展过程中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 562-566.
[15]	刘娟综述, 张澍田审校. 细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 575-578.